Literature DB >> 2525113

Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.

T R Kozel1, M A Wilson, G S Pfrommer, A M Schlageter.   

Abstract

Encapsulated Cryptococcus neoformans yeast cells are potent activators of the complement system. We examined the interaction of the yeast cells with an alternative complement pathway reconstituted from isolated factor D, factor B, factor H, factor I, C3, and properdin. Incubation of encapsulated cryptococci with the reconstituted pathway led to activation and binding of C3 fragments to the yeast cells that was quantitatively and qualitatively identical to that observed with normal human serum. Incubation with either normal serum or a mixture of isolated proteins led to binding of 4 x 10(7) to 5 x 10(7) C3 molecules to the yeast cells. The kinetics for activation and binding of C3 were identical, with maximum binding observed after a 20-min incubation. Immunoglobulin G was not needed for optimal activation kinetics. C3 fragments eluted from the yeast cells by treatment with hydroxylamine and subsequent analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis demonstrated the presence primarily of iC3b on yeast cells incubated with either normal serum or the reconstituted pathway. Ultrastructural examination of the opsonized yeast cells showed that the cryptococcal capsule was the site for binding of C3 activated from normal serum or the reconstituted pathway, with a dense accumulation of C3 at the periphery of the capsule. Thus, incubation of encapsulated cryptococci in the reconstituted pathway led to deposition of opsonic complement fragments at a site that was appropriate for interaction with phagocyte receptors. Cryptococci opsonized with the reconstituted pathway showed a markedly enhanced interaction with cultured human monocytes compared with unopsonized yeast cells, indicating that the alternative pathway alone is opsonic for yeast cells. However, the results indicate that additional serum factors are needed for optimal opsonization of yeast cells because a 35% reduction in the number of cryptococci bound to macrophages was observed with cryptococci opsonized with the reconstituted pathway compared with that observed when yeast cells were opsonized with normal serum.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525113      PMCID: PMC313821          DOI: 10.1128/IAI.57.7.1922-1927.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection.

Authors:  R D Diamond; J E May; M A Kane; M M Frank; J E Bennett
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

2.  Activation of the alternate pathway of human complements by rabbit cells.

Authors:  T A Platts-Mills; K Ishizaka
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

3.  Methods for the study of receptor-mediated phagocytosis.

Authors:  S D Wright
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

4.  C3 shunt activation in human serum chelated with EGTA.

Authors:  D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

5.  Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3.

Authors:  T R Kozel; G S Pfrommer; A S Guerlain; B A Highison; G J Highison
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

6.  Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement.

Authors:  C A Smith; M K Pangburn; C W Vogel; H J Müller-Eberhard
Journal:  J Biol Chem       Date:  1984-04-10       Impact factor: 5.157

7.  Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans.

Authors:  S M Levitz; D J DiBenedetto
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

8.  Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.

Authors:  T R Kozel; G S Pfrommer
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

9.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

10.  Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.

Authors:  S L Newman; L K Mikus
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

View more
  41 in total

Review 1.  Role of phagocytosis in the virulence of Cryptococcus neoformans.

Authors:  Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2004-10

2.  Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.

Authors:  M A Wilson; T R Kozel
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

3.  Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.

Authors:  Marcellene A Gates; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

5.  Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans.

Authors:  R Blackstock; J W Murphy
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

6.  CPS1, a homolog of the Streptococcus pneumoniae type 3 polysaccharide synthase gene, is important for the pathobiology of Cryptococcus neoformans.

Authors:  Y C Chang; A Jong; S Huang; P Zerfas; K J Kwon-Chung
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

7.  Binding of Cryptococcus neoformans to heterologously expressed human complement receptors.

Authors:  S M Levitz; A Tabuni; T R Kozel; R S MacGill; R R Ingalls; D T Golenbock
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

8.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

9.  Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells.

Authors:  T R Kozel; A Tabuni; B J Young; S M Levitz
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

10.  Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.

Authors:  A Vecchiarelli; C Retini; A Casadevall; C Monari; D Pietrella; T R Kozel
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.